Vol 7, No 3 (2021)
Review paper
Published online: 2021-09-06
Page views 5722
Article views/downloads 50
Get Citation

Connect on Social Media

Connect on Social Media

Modern treatment of scabies

Piotr K. Krajewski1, Jacek C. Szepietowski1
Forum Dermatologicum 2021;7(3):73-79.

Abstract

Scabies is a common contagious skin disease caused by the mite Sarcoptes scabiei that affects all people, regardless of age or socioeconomic status. Transmission of scabies most often occurs through direct and prolonged skin contact, which usually happens between family members and sexual partners. The most common form of scabies is classic scabies, the main symptom of which is severe itching that intensifies at night. Tunnels hollowed out by female scabies are typical lesions on the patient’s skin. These changes are mainly located in the interdigital spaces, the proximal phalanges and the flexural surfaces of the wrists. The diagnosis of scabies is mainly based on the clinical picture, but in order to confirm the infestation, adult scabies, their eggs or faeces, must be found by microscopic examination. Treatment of scabies is primarily aimed at eradicating mites as well as managing subjective symptoms and minimizing the risk of transmission. In addition to the use of medicinal preparations for all household members, it is also important to wash and iron all clothes and bedding. According to the European guidelines of 2017, the treatment of scabies is based primarily on the use of topical preparations of permethrin 5% (present in Poland in the form of a cream and gel) or ivermectin used orally at a dose of 200 μg/kg body weight. Both preparations are used twice with a weekly break between doses. Both topical permethrin and ivermectin show a similar, very high cure (over 90%).

Article available in PDF format

Add to basket: 49.00 PLN

Aready have access?

References

  1. Roncalli RA, Roncalli RA. The history of scabies in veterinary and human medicine from biblical to modern times. Vet Parasitol. 1987; 25(2): 193–198.
  2. Fuller LC. Epidemiology of scabies. Curr Opin Infect Dis. 2013; 26(2): 123–126.
  3. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859): 2163–2196.
  4. Jittamala P, Monteiro W, Smit MR, et al. Prevalence of scabies and impetigo worldwide: a systematic review. Lancet Infect Dis. 2015; 15(8): 960–967.
  5. Heukelbach J, Feldmeier H. Scabies. The Lancet. 2006; 367(9524): 1767–1774.
  6. Fimiani M, Mazzatenta C, Alessandrini C, et al. The behaviour of Sarcoptes scabiei var. hominis in human skin: an ultrastructural study. J Submicrosc Cytol Pathol. 1997; 29(1): 105–113.
  7. Currie BJ, McCarthy JS. Permethrin and ivermectin for scabies. N Engl J Med. 2010; 362(8): 717–725.
  8. Johnston G, Sladden M. Scabies: diagnosis and treatment. BMJ. 2005; 331(7517): 619–622.
  9. Arlian LG, Runyan RA, Achar S, et al. Survival and infectivity of Sarcoptes scabiei var. canis and var. hominis. J Am Acad Dermatol. 1984; 11(2 Pt 1): 210–215.
  10. Bouvresse S, Chosidow O, Chosidow O. Clinical practices. Scabies. N Engl J Med. 2006; 354(16): 1718–1727.
  11. Vorou R, Remoudaki HD, Maltezou HC. Nosocomial scabies. J Hosp Infect. 2007; 65(1): 9–14.
  12. Chosidow O. Scabies and pediculosis. The Lancet. 2000; 355(9206): 819–826.
  13. Braun-Falco O, Burgdorf WHC, Plewig G, et al. Dermatologia. T. 1. Wydawnictwo Czelej, Lublin 2017.
  14. Eshagh K, DeKlotz CMC, Friedlander SF. Infant with a papular eruption localized to the back. JAMA Pediatr. 2014; 168(4): 379–380.
  15. Salomon JA, Szepietowski J. Zastosowanie permetryny w leczeniu świerzbu. Dermatologia Kliniczna. 2013; 15(3): 121–125.
  16. Czeschik JC, Huptas L, Schadendorf D, et al. Nodular scabies: hypersensitivity reaction or infection? J Dtsch Dermatol Ges. 2011; 9(10): 840–841.
  17. Buczek A, Blaszak C. Stawonogi: znaczenie epidemiologiczne. Koliber, Lublin 2006.
  18. Kartono F, Lee EW, Lanum D, et al. Crusted Norwegian scabies in an adult with Langerhans cell histiocytosis: mishaps leading to systemic chemotherapy. Arch Dermatol. 2007; 143(5): 626–628.
  19. Kristjansson AK, Smith MK, Gould JW, et al. Pink pigtails are a clue for the diagnosis of scabies. J Am Acad Dermatol. 2007; 57(1): 174–175.
  20. Walter B, Heukelbach J, Fengler G, et al. Comparison of dermoscopy, skin scraping, and the adhesive tape test for the diagnosis of scabies in a resource-poor setting. Arch Dermatol. 2011; 147(4): 468–473.
  21. Dupuy A, Dehen L, Bourrat E, et al. Accuracy of standard dermoscopy for diagnosing scabies. J Am Acad Dermatol. 2007; 56(1): 53–62.
  22. Sonthalia S, Agrawal M, Bhatia J, et al. Entodermoscopy Update: A Contemporary Review on Dermoscopy of Cutaneous Infections and Infestations. Indian Dermatol Online J. 2021; 12(2): 220–236.
  23. Sluzevich JC, Sheth AP, Lucky AW. Persistent eosinophilia as a presenting sign of scabies in patients with disorders of keratinization. Arch Dermatol. 2007; 143(5): 670–673.
  24. Salavastru CM, Chosidow O, Boffa MJ, et al. European guideline for the management of scabies. J Eur Acad Dermatol Venereol. 2017; 31(8): 1248–1253.
  25. Strong M, Johnstone P. Interventions for treating scabies. Cochrane Database Syst Rev. 2007(3): CD000320.
  26. Johnstone P, Strong M. Scabies. BMJ Clin Evid. 2014: 2014.
  27. Thadanipon K, Anothaisintawee T, Rattanasiri S, et al. Efficacy and safety of antiscabietic agents: A systematic review and network meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2019; 80(5): 1435–1444.
  28. Ranjkesh MR, Naghili B, Goldust M, et al. The efficacy of permethrin 5% vs. oral ivermectin for the treatment of scabies. Ann Parasitol. 2013; 59(4): 189–194.
  29. Ahmad HM, Abdel-Azim ES, Abdel-Aziz RT. Clinical efficacy and safety of topical versus oral ivermectin in treatment of uncomplicated scabies. Dermatol Ther. 2016; 29(1): 58–63.
  30. Chhaiya SB, Patel VJ, Dave JN, et al. Comparative efficacy and safety of topical permethrin, topical ivermectin, and oral ivermectin in patients of uncomplicated scabies. Indian J Dermatol Venereol Leprol. 2012; 78(5): 605–610.
  31. Goldust M, Rezaee E. The efficacy of topical ivermectin versus malation 0.5% lotion for the treatment of scabies. J Dermatolog Treat. 2013 [Epub ahead of print].
  32. Szepietowski J, Baran W. Terapia w dermatologii. PZWL Wydawnictwo Lekarskie, Warszawa 2019.
  33. Laing R, Gillan V, Devaney E. Ivermectin - Old Drug, New Tricks? Trends Parasitol. 2017; 33(6): 463–472.
  34. Ashour DS. Ivermectin: From theory to clinical application. Int J Antimicrob Agents. 2019; 54(2): 134–142.
  35. Rosumeck S, Nast A, Dressler C, et al. Ivermectin and permethrin for treating scabies. Cochrane Database Syst Rev. 2018; 4(6): CD012994–732.
  36. Chiu S, Argaez C. Ivermectin for Parasitic Skin Infections of Scabies: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness, and Guidelines. CADTH Rapid Response Reports, Ottawa 2019.
  37. AL Ja, Amin M. Comparison the effectiveness of sulphur ointment, permethrin and oral ivermectin in treatment of scabies. Research Journal of Pharmaceutical, Biological and Chemical Sciences. 2018; 9(1): 670–676.
  38. Workowski KA, Bolan GA. Centers for Disease C, Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015; 64(RR-03): 1–137.
  39. Bécourt C, Marguet C, Balguerie X, et al. Treatment of scabies with oral ivermectin in 15 infants: a retrospective study on tolerance and efficacy. Br J Dermatol. 2013; 169(4): 931–933.
  40. Karthikeyan K. Treatment of scabies: newer perspectives. Postgrad Med J. 2005; 81(951): 7–11.
  41. Zawar V, Pawar M. Liquid nitrogen cryotherapy in the treatment of chronic, unresponsive nodular scabies. J Am Acad Dermatol. 2017; 77(2): e43–e44.
  42. Mittal A, Garg A, Agarwal N, et al. Treatment of nodular scabies with topical tacrolimus. Indian Dermatol Online J. 2013; 4(1): 52–53.